Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARαin rats fed a high-fat diet

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2692-2706

  Kou, Xin Hui ^a   Zhu, Mei Feng ^b   Chen, Dai ^b   Lu, Yi ^a   Song, Hui Zhu ^a   Ye, Jian Lin ^a   Yue, Lin Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Insulin resistance; Lipid metabolism; Phosphorylation; PKA; PPAR

Indexed keywords

ALANINE; ANTILIPEMIC AGENT; BILOBETIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FATTY ACID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RADIOISOTOPE; SERINE; THREONINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FATTY ACID OXIDATION; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; MALE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIET, HIGH-FAT; FLAVONOIDS; HEPATOCYTES; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MUSCLE, SKELETAL; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84859082774     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01727.x     Document Type: Article

References (48)

1. Achouri Y, Hegarty BD, Allanic D (2005). Long chain fatty acyl CoA synthetase 5 expression is induced by insulin and glucose: involvement of sterol regulatory element-binding protein-1c. Biochimie 87: 1149-1155. (Pubitemid 41572644)
2. Adiels M, Olofsson SO, Taskinen MR, Boren J (2006). Diabetic dyslipidaemia. Curr Opin Lipidol 17: 238-246. (Pubitemid 43786057)
3. Alwayn I, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM et al. (2006). Inhibition of matrix metalloproteinases increases PPAR-α and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol 291: G1011-G1019. (Pubitemid 44904155)
4. Applebaum-Bowden D (1995). Lipases and lecithin: cholesterol acyltransferase in the control of lipoprotein metabolism. Curr Opin Lipidol 6: 130-135.
5. 13C-labeling pattern of glucose by gas chromatography-mass spectrometry. Anal Biochem 212: 526-531.
6. Bieber LL, Abraham T, Helmarath T (1972). A rapid spectrophotometric assay for carnitine palmitoyltransferase. Anal Biochem 50: 509-518.
7. Burns KA, Vanden-Heuvel JP (2007). Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771: 952-960. (Pubitemid 47198547)
8. Chandra V, Huang PX, Hamuro Y, Raghuram S, Wang YJ, Burris TP et al. (2008). Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA. Nature 456: 350-356.
9. Chavez JA, Summers SA (2005). Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 419: 101-109. (Pubitemid 37329976)
10. Chen W, Zhou XB, Liu HY, Xu C, Wang LL, Li S (2009). P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice. Br J Pharmacol 157: 724-735.
11. Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159. (Pubitemid 17064313)
12. Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G et al. (2010). Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol 160: 1892-1902.
13. Desvergne B, Wahli W (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688. (Pubitemid 30650602)
14. Doha KO, Kima YW, Parka SY, Leea SK, Parkb JS, Kim JY (2005). Interrelation between long-chain fatty acid oxidation rate and carnitine palmitoyltransferase 1 activity with different isoforms in rat tissues. Life Sci 77: 435-443.
15. Dole V, Meinertz H (1960). Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 235: 2595-2599.
16. Dommes V, Baumgart C, Kumnau WH (1981). Degradation of unsaturated fatty acids in peroxisomes. Existence of 2,4-dienoyl-CoA reductase pathway. J Biol Chem 256: 8259-8262. (Pubitemid 12254775)
17. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC (2004). Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53: 890-898. (Pubitemid 38436600)
18. Ginsberg HN, Zhang YL, Hernandez-Ono A (2006). Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14: 41S-49S.
19. Gómez-Garre D, Herraíz M, González-Rubio ML, Bernal R, Aragoncillo P, Carbonell A et al. (2006). Activation of peroxisome proliferator-activated receptor-α and-γ in auricular tissue from heart failure patients. Eur J Heart Fail 8: 154-161. (Pubitemid 43240849)
20. Gray JP, Burns KA, Leas TL, Perdew GH, Vanden-Heuvel JP (2005). Regulation of peroxisome proliferator-activated receptor α by protein kinase C. Biochemistry 44: 10313-10321. (Pubitemid 41076826)
21. Harwood HJ (1962). Reactions of the hydrocarbon chain of fatty acids. Chem Rev 62: 102-103.
22. Honkakoski P, Zelko I, Sueyoshi T, Negishi M (1998). The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital- responsive enhancer module of the CYP2B gene. Mol Cell Biol 18: 5652-5658. (Pubitemid 28450516)
23. Hosokawa Y, Shimomura Y, Harris RA (1989). Determination of short-chain acyl CoA esters by high-performance liquid chromatography. Anal Biochem 153: 45-49.
24. Hultin M, Carneheim C, Rosenqvist K, Olivecrona T (1995). Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 36: 2174-2184.
25. Ide T, Watanabe M, Sugano M, Yamamoto I (1987). Activities of liver mitochondrial and peroxisomal fatty acid oxidation enzymes in rats fed trans fat. Lipids 22: 6-10. (Pubitemid 17000469)
26. Iverius PH, Lindqvist AM (1986). Preparation, characterization and measurement of lipoprotein lipase. Methods Enzymol 129: 691-704.
27. Jordan M, Schallhorn A, Wurm FM (1996). Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24: 596-601. (Pubitemid 26085833)
28. Kaluzny M, Duncan L, Merritt M, Epps D (1985). Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res 26: 135-140. (Pubitemid 15133302)
29. Laplante M, Festuccia WT, Soucy G, Blanchard PG, Renaud A, Berger JP et al. (2009). Tissue-specific postprandial clearance is the major determinant of PPARγ-induced triglyceride lowering in the rat. Am J Physiol Regul Integr Comp Physiol 296: R57-R66.
30. Lazennec G, Canaple L, Saugy D, Wahli W (2000). Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 14: 1962-1975. (Pubitemid 32055530)
31. Lewis GF, Carpentier A, Adeli K, Giacca A (2002). Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229. (Pubitemid 34299024)
32. Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q et al. (2006). The PPAR alpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol 148: 610-618. (Pubitemid 43993051)
33. Maessen JG, Vusse GJ, Vork M, Kootstra G (1988). Nucleotides, nucleosides and oxypurines in human kidneys measured by use of reversed phase high-performance liquid chromatography. Clin Chem 34: 1087-1090.
34. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997). Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγactivators. J Biol Chem 272: 28210-28217. (Pubitemid 27517759)
35. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA et al. (2006). Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6: 87-97.
36. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N (1998). Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 273: 16710-16714. (Pubitemid 28311694)
37. Oakes ND, Kjellstedt A, Forsberg G, Clementz T, Camejo G, Furler S (1999). Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2-bromopalmitate tracer. J Lipid Res 40: 1155-1169. (Pubitemid 29287887)
38. Ringseis R, Muschick A, Eder K (2007). Dietary oxidized fat prevents ethanol induced triacylglycerol accumulation and increases expression of PPARα target genes in rat liver. J Nutr 137: 77-83. (Pubitemid 46052862)
39. Rong X, Li Y, Ebihara K, Zhao M, Kusakabe T, Tomita T et al. (2010). Irbesartan treatment up-regulates hepatic expression of PPAR-alpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. Br J Pharmacol 160: 1796-1807.
40. Rössner S (1974). Studies on an intravenous fat tolerance test. Methodological, experimental and clinical experiences with Intralipid. Acta Med Scand Suppl 564: 1-24.
41. Saponara R, Bosisio E (1998). Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue. J Nat Prod 61: 1386-1387. (Pubitemid 28555104)
42. Schwarz JM, Linfoot P, Dare D, Aghajanian K (2003). Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77: 43-50. (Pubitemid 36015371)
43. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL (2006). Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 285: 35-50.
44. Taskén K, Aandahl EM (2004). Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84: 137-167. (Pubitemid 38049878)
45. Taube A, Eckardt K, Eckel J (2009). Role of lipid-derived mediators in skeletal muscle insulin resistance. Am J Physiol Endocrinol Metab 297: E1004-E1012.
46. Wang F, Tong Q (2009). SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARγ. Mol Biol Cell 20: 801-808.
47. Woo CW, Siow YL, O K (2006). Homocysteine activates cAMP-response element binding protein in HEK293 through cAMP/PKA signaling pathway. Arterioscler Thromb Vasc Biol 26: 1043-1050. (Pubitemid 43732110)
48. Ye JM, Tid-Ang J, Turner N, Zeng XY, Li HY, Cooney GJ et al. (2011). PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br J Pharmacol 163: 556-566.